Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have earned an average rating of “Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $18.94.
A number of research analysts have recently weighed in on the company. Zacks Investment Research raised ProQR Therapeutics from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a research report on Wednesday. ValuEngine cut ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. Leerink Swann reaffirmed an “outperform” rating and set a $12.00 price objective (up from $10.00) on shares of ProQR Therapeutics in a research report on Tuesday, September 26th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of ProQR Therapeutics in a research report on Tuesday, September 26th. Finally, JMP Securities lifted their price objective on ProQR Therapeutics from $14.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, September 26th.
Several hedge funds have recently bought and sold shares of PRQR. Artal Group S.A. lifted its position in shares of ProQR Therapeutics by 25.0% during the 2nd quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $2,600,000 after buying an additional 100,000 shares in the last quarter. Janus Henderson Group PLC purchased a new position in shares of ProQR Therapeutics during the 2nd quarter valued at about $2,028,000. Redmile Group LLC lifted its position in shares of ProQR Therapeutics by 2.8% during the 2nd quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock valued at $8,301,000 after buying an additional 43,050 shares in the last quarter. Nine Chapters Capital Management LLC purchased a new position in ProQR Therapeutics in the 3rd quarter worth approximately $133,000. Finally, Sphera Funds Management LTD. lifted its holdings in ProQR Therapeutics by 60.6% in the 3rd quarter. Sphera Funds Management LTD. now owns 530,000 shares of the biopharmaceutical company’s stock worth $2,571,000 after purchasing an additional 200,000 shares in the last quarter. 31.63% of the stock is currently owned by hedge funds and other institutional investors.
ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings data on Monday, November 20th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.03. equities analysts anticipate that ProQR Therapeutics will post -1.71 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “ProQR Therapeutics N.V. (PRQR) Receives Consensus Recommendation of “Buy” from Brokerages” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/01/12/proqr-therapeutics-n-v-prqr-receives-consensus-recommendation-of-buy-from-brokerages.html.
About ProQR Therapeutics
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.